The current treatment landscape for indolent systemic mastocytosis
4 Views
administrator
07/09/23
Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, gives an overview of the current treatment landscape for indolent systemic mastocytosis, highlighting mainstay agents such as proton pump inhibitors, mast cell stabilizers, and leukotriene blockers. Dr Bose also comments on the importance of monitoring bone density. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
-
Category
Show more
Facebook Comments
No comments found